Skip to content

Advancing the public health applications of Chlamydia trachomatis serology

Research output: Contribution to journalArticle

  • Sarah C Woodhall
  • Rachel Gorwitz
  • Migchelsen Stephanie J
  • Sami L Gottlieb
  • Paddy J Horner
  • William M Geisler
  • C Winstanley
  • Katrin Hufnagel
  • Tim Waterboer
  • Diana Martin
  • W M Huston
  • Charlotte A Gaydos
  • Carolyn Deal
  • Magnus Unemo
  • J K Dunbar
  • Kyle Bernstein
Original languageEnglish
JournalLancet Infectious Diseases
Early online date5 Jul 2018
DateAccepted/In press - 9 Feb 2018
DateE-pub ahead of print (current) - 5 Jul 2018


Genital Chlamydia trachomatis infection is the most commonly diagnosed sexually transmitted infection. Trachoma is caused by ocular infection with C trachomatis and is the leading infectious cause of blindness worldwide. New serological assays for C trachomatis could facilitate improved understanding of C trachomatis epidemiology and prevention. C trachomatis serology offers a means of investigating the incidence of chlamydia infection and might be developed as a biomarker of scarring sequelae, such as pelvic inflammatory disease. Therefore, serological assays have potential as epidemiological tools to quantify unmet need, inform service planning, evaluate interventions including screening and treatment, and to assess new vaccine candidates. However, questions about the performance characteristics and interpretation of C trachomatis serological assays remain, which must be addressed to advance development within this field. In this Personal View, we explore the available information about C trachomatis serology and propose several priority actions. These actions involve development of target product profiles to guide assay selection and assessment across multiple applications and populations, establishment of a serum bank to facilitate assay development and evaluation, and development of technical and statistical methods for assay evaluation and analysis of serological findings. The field of C trachomatis serology will benefit from collaboration across the public health community to align technological developments with their potential applications.

Download statistics

No data available



  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 1 MB, PDF document


View research connections

Related faculties, schools or groups